Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4
In patients with slowly progressive spastic paraparesis, the differential diagnosis of primary progressive multiple sclerosis (PPMS) and hereditary spastic paraplegia (HSP) can be challenging. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are promising fluid biom...
Main Authors: | Christoph Kessler, Christoph Ruschil, Ahmed Abdelhak, Carlo Wilke, Aleksandra Maleska, Jens Kuhle, Markus Krumbholz, Markus C. Kowarik, Rebecca Schüle |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/21/13466 |
Similar Items
-
Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer’s disease
by: Tangni Fang, et al.
Published: (2024-01-01) -
Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer’s disease
by: Tandis Parvizi, et al.
Published: (2022-08-01) -
The potential of serum S100 calcium-binding protein B and glial fibrillary acidic protein as biomarkers for traumatic brain injury
by: Seke Nzau Mafuika, et al.
Published: (2022-11-01) -
JASPAC: Japan Spastic Paraplegia Research Consortium
by: Kishin Koh, et al.
Published: (2018-08-01) -
Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria
by: Amelie S. Lotz-Havla, et al.
Published: (2022-09-01)